Evidence map›Paper›PMID 39131374›Full record

ArticlebioRxiv : the preprint server for biology2024

Stromal KITL/SCF promotes pancreas tissue homeostasis and restrains tumor progression.

M Kathrina Oñate, Chet Oon, Sohinee Bhattacharyya, Vivien Low, Canping Chen, Xiaofan Zhao, Ziqiao Yan, Yan Hang, Seung K Kim, Zheng Xia and 1 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

M Kathrina OñateCancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Chet OonCancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Sohinee BhattacharyyaCancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Vivien LowCancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Canping ChenDepartment of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon.
Xiaofan ZhaoDepartment of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon.
Ziqiao YanDepartment of Developmental Biology, Stanford University School of Medicine, Stanford, California.
Yan HangDepartment of Developmental Biology, Stanford University School of Medicine, Stanford, California.
Seung K KimDepartment of Developmental Biology, Stanford University School of Medicine, Stanford, California.
Zheng XiaDepartment of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon.
Mara H ShermanCancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Understanding the origins of rapid recurrence of pancreatic cancer after resectionP30CA069533 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Grace B Gill · 1997 to 2026
$60.5M
Project 3: Impact of tumor genetics on PDAC immunobiology and responses to macrophage-targeted immunotherapyP01CA244114 · NCI · STANFORD UNIVERSITY · PI KIM, SEUNG K · 2021 to 2025
$10.0M
Identifying and Targeting Metabolic Dependencies in the Pancreatic Tumor MicroenvironmentR01CA229580 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Mara H. Sherman · 2018 to 2026
$3.8M
Origins and functions of pancreatic cancer-associated fibroblastsR01CA250917 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Mara H. Sherman · 2021 to 2026
$2.3M
Characterizing phenotype-associated subpopulations from single-cell sequencing dataR01GM147365 · NIGMS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Zheng Xia · 2023 to 2026
$1.2M
NCI NIH HHS P01 CA244114NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA069533NCI NIH HHS R01 CA229580NCI NIH HHS R01 CA250917NIGMS NIH HHS R01 GM147365
6 · The paper itself

Abstract

Components of normal tissue architecture serve as barriers to tumor progression. Inflammatory and wound-healing programs are requisite features of solid tumorigenesis, wherein alterations to immune and non-immune stromal elements enable loss of homeostasis during tumor evolution. The precise mechanisms by which normal stromal cell states limit tissue plasticity and tumorigenesis, and which are lost during tumor progression, remain largely unknown. Here we show that healthy pancreatic mesenchyme expresses the paracrine signaling molecule KITL, also known as stem cell factor, and identify loss of stromal KITL during tumorigenesis as tumor-promoting. Genetic inhibition of mesenchymal KITL in the contexts of homeostasis, injury, and cancer together indicate a role for KITL signaling in maintenance of pancreas tissue architecture, such that loss of the stromal KITL pool increased tumor growth and reduced survival of tumor-bearing mice. Together, these findings implicate loss of mesenchymal KITL as a mechanism for establishing a tumor-permissive microenvironment.

Indexed as

mesenchymal cellspancreatic cancerparacrine signalingtissue plasticity

Identifiers

PMID39131374
PMCPMC11312444

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.